![Distribution of individual viral load test results by age and period.](JIAS-19-21264-g001){#F0001_008}

###### 

Distribution of viral load test results by age category and calendar year

               0--1 years     1--4 years     5--9 years      10--14 years    15--19 years
  ------------ -------------- -------------- --------------- --------------- --------------
  2004--2007   11,593 (15%)   27,157 (35%)   24,921 (32%)    8854 (11%)      5904 (8%)
  2008--2011   29,983 (9%)    88,391 (26%)   110,737 (33%)   72,774 (22%)    34,981 (10%)
  2012--2014   31,299 (6%)    89,530 (17%)   155,163 (30%)   141,945 (28%)   96,042 (19%)

###### 

Predictors of death \>6 months of cART

  Variable                                                                                                                     Adjusted HR (95% CI)   P
  -------------------------------------------------------------------------------- ------------------------------------------- ---------------------- ---------
  Country type                                                                     Middle-income (Russia, Ukraine, Thailand)   ref                    0.028
                                                                                   High-income                                 0.5 (0.2--0.9)         
  Calendar year at cART start                                                      1997--\<2004                                ref                    0.035
                                                                                   2004--\<2008                                0.4 (0.2--0.8)         
                                                                                   ≥2008                                       0.5 (0.1--1.5)         
  BMI-for-age z-score at cART start                                                \>0                                         0.2 (0.1--0.6)         0.045
                                                                                   −3 to 0                                     ref                    
                                                                                   \<−3                                        0.5 (0.2--1.6)         
  VL copy-years suppressed (≤400 c/ml) since cART Initiation (per year increase)                                               0.7 (0.6--0.9)         0.001
  Current (time updated) age (years)                                               \<2                                         4.2 (1.4--12.7)        0.002
                                                                                   2--\<5                                      0.2 (0.1--1.8)         
                                                                                   5--\<l4                                     ref                    
                                                                                   ≥14                                         2.1 (1.0--4.2)         
  Current (time updated) WHO immune stage severe                                   No                                          0.1 (0.1--0.2)         \<0.001
                                                                                   Yes                                         ref                    
  Current (time updated) BMl-for-age z-score                                       \>0                                         1.1 (0.4--2.8)         \<0.001
                                                                                   −3 to 0                                     ref                    
                                                                                   \<−3                                        19.5 (7.2--52.8)       

###### 

Characteristics of children with presumed perinatal HIV infection who remain in care at the original site (RIC) or are transferred out (TFO)

                                                                      RIC (n=2650) (excludes 253 children deceased or LTFU)   TFO (n=917)         p
  ------------------------------------------------------------------- ------------------------------------------------------- ------------------- ---------
  Female (n/N; %)                                                     1260/2650; 48%                                          439/917; 48%        0.865
  Median (IQR) age in years at ART start                              7.2 (5.6--8.4)                                          7.1 (5.4--8.3)      0.195
  WHO-defined severe immunosuppression at ART start (n/N; %)          993/1461; 68%                                           433/627; 69%        0.623
  Median (IQR) age (years) at TFO or last visit if RIC                12.1 (10.9--13.8)                                       11.4 (10.6--12.7)   \<0.001
  Median (IQR) CD4 (cells/µl) at TFO or last visit if RIC             725 (518--950)                                          779 (569--1032)     \<0.001
  CD4 \>500 cells/µl at TFO or last visit if RIC (n/N; %)             1566/2036; 77%                                          656/801; 82%        0.004
  Height-for-age z-score \<--2 at TFO or last visit if RIC (n/N; %)   355/906; 39%                                            221/543; 41%        0.568
  HIV-RNA \<400 copies/ml (n/N; %)                                    1543/2117; 73%                                          694/781; 89%        \<0.001

![Cumulative incidence of switch at 3 years of ART by age at start of ART, initial regimen and monitoring strategy by region.](JIAS-19-21264-g002){#F0039_011}

![Distribution of individual viral load test results by age and period.](JIAS-19-21264-g003){#F0002_008}

![Retention in adherence club care -- community vs clinic-based clubs.](JIAS-19-21264-g004){#F0004_014}

![Effect of patient transfer on retention estimates.](JIAS-19-21264-g005){#F0005_016}

###### 

Summary of time interval between single dose RPV and baseline PK

  Sex      Single Dose (SD) of RPV   Plasma RPV at 24 hours after SD RPV (ng/ml) Mean (±STD)   Time (Days) between SD and Multiple Dose (MD) Baseline Visit Mean (±STD)   Plasma RPV at MD Baseline Visit (ng/ml) Mean (±STD)
  -------- ------------------------- --------------------------------------------------------- -------------------------------------------------------------------------- -----------------------------------------------------
  Male     600 mg (N=2)              20.9 (12.3)                                               630 (100)                                                                  0.8 (0.8)
           1200 mg (N=2)             18.2 (3.7)                                                553 (51)                                                                   3.7 (1.1)
  Female   1200 mg (N=5)             54.0 (12.1)                                               536 (182)                                                                  4.8 (2.9)

![Estimates of (a) HIV incidence rates per 10,000; (b) undiagnosed HIV prevalence rates per 10,000; and (c) median time from infection to diagnosis (months).](JIAS-19-21264-g006){#F0006_024}

![Adjusted HIV incidence and 95% CIs, by sex and age-group.](JIAS-19-21264-g007){#F0007_025}

###### 

Adjusted HIV incidence and 95% CI, total and by urbanicity

  Demographic group   Participants   Incident infections   Follow-up person years   Crude IR per 100 person years   Adjusted IR per 100 person years
  ------------------- -------------- --------------------- ------------------------ ------------------------------- ----------------------------------
  Total               10,826         473                   8195.8                   5.8 (5.3--6.3)                  4.7 (4.2--5.4)
  Chokwe Town         6670           329                   4733.1                   7.0 (6.2--7.7)                  6.0 (5.2--6.9)
  Villages            4152           144                   3462.6                   4.2 (3.5--4.9)                  3.4 (2.8--4.2)

![Unsuppressed HIV prevalence and population viral suppression in South African districts.](JIAS-19-21264-g008){#F0008_026}

###### 

Women: childhood traumas associated with HIV risks

                                              Childhood trauma mean (CI 95%)                                        
  ------------------------------------------- -------------------------------- ---------------- ------------------- -----------
  3 or more once-off sexual partners          9.1 (7.5--10.7)                  5.7 (5.0--6.4)   1.08 (1.00--1.16)   p\<0.05
  Experience of physical and/or sexual IPV    7.2 (6.5--8.0)                   4.6 (3.8--5.4)   1.08 (1.01--1.15)   p\<0.05
  Experience of non-partner sexual violence   9.3 (8.1--10.5)                  4.9 (4.3--5.4)   1.13 (1.06--1.21)   p\<0.0001
  Problematic alcohol use                     9.4 (7.9--10.9)                  5.4 (4.8--5.9)   1.07 (1.00--1.15)   p\<0.05

###### 

Men: childhood traumas associated with HIV risks

                                             Childhood trauma mean (CI)                                        
  ------------------------------------------ ---------------------------- ---------------- ------------------- -----------
  3 or more main sexual partners             8.8 (7.5--10.0)              6.7 (5.9--7.6)   1.08 (1.02--1.13)   p\<0.01
  3 or more casual sexual partners           9.2 (7.5--10.8)              6.9 (6.1--7.7)   1.06 (1.00--1.11)   p\<0.05
  3 or more once-off sexual partners         8.7 (7.3--10.1)              7.0 (6.1--7.8)   1.06 (1.00--1.11)   p\<0.05
  Perpetrating any IPV                       9.3 (8.3--10.2)              5.1 (4.2--6.0)   1.14 (1.07--1.21)   p\<0.0001
  Perpetrating non-partner sexual violence   9.5 (8.3--10.7)              6.1 (5.3--6.9)   1.07 (1.02--1.13)   p\<0.01

###### 

Pressing research gaps relevant to pregnancy and HIV

  Treatment                                                                                                                                           Co-infection and co-morbidities                                                                                                                                       Other/cross-cutting
  --------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------
  Choice of ARV to optimize short and long term maternal healthOptimal dosing throughout pregnancyContinuation of therapy after treatment for PMTCT   Safety and efficacy of treatment for HIV+ pregnant women with:TB and malariaOpportunistic infectionsHepatitis B and CHypertension, eclampsia, pre-eclampsiaDiabetes   PK studiesNew delivery mechanisms (e.g. rings and patches)HIV and fertility
                                                                                                                                                                                                                                                                                                                            
  **Prevention**                                                                                                                                      **Diagnostics**                                                                                                                                                       **Vaccines**
                                                                                                                                                                                                                                                                                                                            
  Chemoprevention (PrEP, microbicides)Safe conception                                                                                                 Optimal HIV testing throughout pregnancyResistance testing                                                                                                            HIV vaccine trialsOther vaccine trials with HIV-infected participants

###### 

Barriers to conducting clinical research relevant to pregnancy and HIV

  Ethical                                                                                                                                                                                                                                                                                         Legal                                                                                                                                                                                                                                                                       Research environment and culture
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Calculating risk/benefit ratioEnsuring informed consent, including what role, if any, the biological father should have in decision makingBurden on pregnant women of research study requirements                                                                                               Difficulty interpreting US human subjects regulations related to pregnant women (what is "minimal risk" in clinical research?)Concerns about study disapproval by IRBsStudies with pregnant minors raise additional regulatory concernsLiability if study results in harm   Reputational risk to the researcher if study results in foetal harmBelief that funders, regulators, and public would only view observational studies as ethicalEasier to obtain funding and conduct research with other populations
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  **Financial**                                                                                                                                                                                                                                                                                   **Analytical**                                                                                                                                                                                                                                                              **Logistical**
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Required follow-up and potential ancillary care for women who become pregnant on study are costlyPharma does not perceive pregnant women as a lucrative market segment (little incentive to study with potential liability as a disincentive)Funders fail to prioritize research on pregnancy   Data from pregnant women or women who become pregnant during study must be analyzed separatelyLow statistical power due to likely small sample size                                                                                                                         Most trials do not enrol pregnant women and require women who become pregnant to withdraw, so even conducting opportunistic or observational studies is difficultNeed for "buy-in" from men for studies in many international settingsLocating participants for data collection at fixed time points in pregnancy

###### 

Knowledge of HIV prevention strategies for conception by known HIV status among 391 female sex workers in Port Elizabeth, South Africa

                                         Overall, n=391   HIV−, n=142   HIV+, no prior dx, n=46   HIV+, prior dx, n=203   p-value
  -------------------------------------- ---------------- ------------- ------------------------- ----------------------- ---------
  ARVs for the infected partner                                                                                           
   No                                    300 (76.7)       113 (79.6)    42 (91.3)                 145 (71.4)              0.007
   Yes                                   91 (23.3)        29 (20.4)     4 (8.7)                   58 (28.6)               
  PrEP for the uninfected partner                                                                                         
   No                                    374 (95.7)       135 (95.1)    45 (97.8)                 194 (95.6)              0.883
   Yes                                   17 (4.4)         7 (4.9)       1 (2.2)                   9 (4.4)                 
  Treatment when pregnant                                                                                                 
   No                                    203 (51.9)       91 (64.1)     30 (65.2)                 82 (40.4)               \<0.001
   Yes                                   188 (48.1)       51 (35.9)     16 (34.8)                 121 (59.6)              
  Self-insemination                                                                                                       
   No                                    387 (99.0)       140 (98.6)    46 (100.0)                201 (99.0)              1.00
   Yes                                   4 (1.0)          2 (1.4)       0 (0.0)                   2 (1.0)                 
  Timed intercourse                                                                                                       
   No                                    387 (99.0)       140 (98.6)    46 (100.0)                201 (99.0)              1.00
   Yes                                   4 (1.0)          2 (1.4)       0 (0.0)                   2 (1.0)                 
  Sperm-washing/in-vitro fertilization                                                                                    
   No                                    363 (92.8)       130 (91.6)    44 (95.7)                 189 (93.1)              0.694
   Yes                                   28 (7.2)         12 (8.4)      2 (4.3)                   14 (6.9)                
  Using a sperm donor                                                                                                     
   No                                    360 (92.1)       132 (93.0)    46 (100.0)                182 (89.7)              0.038
   Yes                                   31 (7.9)         10 (7.0)      0 (0.0)                   21 (10.3)               
  Adoption                                                                                                                
   No                                    300 (76.7)       109 (76.8)    44 (95.7)                 147 (72.4)              0.001
   Yes                                   91 (23.3)        33 (23.2)     2 (4.3)                   56 (27.6)               

![Cumulative number of Sexual Partners by Sexual Orientation.](JIAS-19-21264-g009){#F0049_042}
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=========

1\. Ministry of Education. (2015). Retrieved from: <http://www.moh.gov.cn/jkj/s3585/201508/e4c8a1e6809c4a8e9c49f7f8708873d1.shtml>

###### 

Association between MM visit exposure and key behavioural and PMTCT uptake indicators

                                                                                                      Adjusted odds ratios   Unadjusted Frequencies         
  --------------------------------------------------------- ----------------------------------------- ---------------------- ------------------------ ----- -----
  Maternal Behavioural Outcomes                             Using family planning                     1.26                   0.012                    74%   65%
                                                            Exclusive breast feeding first 6 months   1.67                   \<0.001                  84%   75%
  Uptake of Maternal PMTCT Services                         Antenatal prophylaxis                     3.86                   \<0.001                  96%   77%
                                                            Postnatal prophylaxis                     2.27                   \<0.001                  86%   74%
  Uptake of Infant PMTCT Services                           Infant prophylaxis                        1.60                   0.017                    96%   93%
                                                            Infant CPT                                1.63                   0.001                    78%   72%
                                                            6--8 week PCR test                        2.31                   \<0.001                  75%   52%
  Impact - Mother-to-Child Transmission Rate at 18 Months   Infant HIV status HIV-negative            6.4                    \<0.001                  93%   70%

![Abstract TUAX0101LB--Viral load kinetics following treatment interruption in VHM + ART vs. ART arms](JIAS-19-21264-g010){#F0040_054}

###### 

Abstract TUAX0101LB--Characteristics at randomization and after TI in VHM + ART vs. ART arms

  Characteristics, median (range)                           VHM + ART                      ART
  --------------------------------------------------------- ------------------------------ ------------------------------
  Age at randomization, years/gender                        28 (22--51)/9 male: 1 female   26 (24--34)/4 male: 1 female
  ART duration, weeks                                       224 (79--294)                  155 (100--295)
  CD4 count, cells/mm^3^                                    634 (501--1106)                1079 (537--1612)
  Total HIV DNA (copies/10E6 PBMCs)                         837 (0--2323)                  594 (19--1878)
  POST-TREATMENT INTERRUPTION                                                              
  Time from treatment interruption to VL detection, weeks   3 (2--5)                       3.1 (3--11)
  VL levels at first detection, copies/ml                   222 (33--41,822)               156 (52--395)
  Time from first VL detection to ART resumption, weeks     1 (0.1--4.1)                   2 (1--5.3)
  Time from ART resumption to VL suppression, weeks         2.9 (0.9--10.9)                2 (1.9--3.9)

###### 

Abstract TUAX0103LB--Programme data May 2014--Mar 2016

                                       SAPPH-IRe sites   Usual Care Sisters sites
  ------------------------------------ ----------------- --------------------------
  \# community mobilisation meetings   537               145
  \# peer educator contacts            17,013            13,151
  \# FSW seen                          4549              3574
  \# FSW clinic attendances            12,905            10,031
  \# HIV tests                         2606              1151
  \# ART on-site initiations           768               0
  \# On-site PrEP initiations          487               0
  \# Adherence sisters paid            514               0

![Tenofovir diphosphate levels (fmol/punch) and PrEP dosing estimates via DBS.](JIAS-19-21264-g011){#F0041_057}

![Distribution by region over time.](JIAS-19-21264-g012){#F0042_058}

###### 

Virological suppression after ART initiation at different CD4 count thresholds

  CD4 Count at Initiation (cells/µl)   3 months         6 months          12 months        18 months
  ------------------------------------ ---------------- ----------------- ---------------- ---------------
  \<350 (n=77)                         87.9% (51/58)    85.9% (67/78)     87.8% (65/74)    92.8% (65/70)
  ≥350 (n=80)                          95.3% (61/64)    92.7% (51/55)     92.1% (35/38)    100% (26/26)
  P-value                              0.190            0.273             0.544            0.319
  \<500 (n=132)                        92.2% (94/102)   88.5% (100/113)   88.0% (88/100)   94.4% (85/90)
  ≥500 (n=35)                          90.0% (18/20)    90.0% (18/20)     100% (12/12)     100% (6/6)
  P-value                              1.000            1.000             0.357            1.000

###### 

Baseline characteristics of HIV patients with newly diagnosed PTB randomized to three ATT regimens

                                               Daily regimen A (n=110)   Part daily regimen B (n=109)   Intermittent regimen C (n=105)
  -------------------------------------------- ------------------------- ------------------------------ --------------------------------
  Mean age in years ±SD                        38±8                      39±9                           39±9
  Mean weight in kilograms ±SD                 42.6±8.1                  42.0±7.5                       44.4±7.5
  Mean HB gms %±SD                             9.7±2.2                   9.6±2.0                        10.0±2
  Mean HCT %±SD                                28.7±6.6                  27.8±5.3                       29.8±7.1
  Mean HIV viral load(log~10~){copies/ml}±SD   4.8±1.2                   4.9±1.0                        4.9±1.2
  Median CD4 cell count (IQR)cells/mm^3^       130 (65--220)             145 (79--262)                  135 (65--252)
  Median ATT-ART interval (IQR), in days       17 (3--36)                17 (5--45)                     15 (2--34)
  Mycobacterium TB sensitive to all drugs %    77                        71                             68

![Survival by CMV status: whole cohort and stratified by age. (a) Survival by CMV status, all patients; (b) patients aged less than 36 years; (c) patients aged 36 years and older.](JIAS-19-21264-g013){#F0009_071}

###### 

Cox proportional hazards regression analysis of factors associated with 12-week mortality

                                                    Univariate   Multivariate: n=232 with complete observations                                             
  ------------------------------------------------- ------------ ------------------------------------------------ ------ ------------- ------ ------ ------ -------------
  Age, per 10 years                                 1.75         1.41                                             2.19   **\<0.001**   1.70   1.34   2.15   **\<0.001**
  Male sex                                          0.84         0.50                                             1.41   0.505         0.69   0.41   1.19   0.185
  CD4, per 50 cells×10^6^ l                         0.78         0.64                                             0.96   **0.017**     0.80   0.64   1.00   0.052
  HIV viral load, Log10 copies/ml                   0.90         0.80                                             1.03   0.117         0.94   0.82   1.07   0.316
  Mycobacteraemia                                   1.48         0.88                                             2.49   0.138         1.00   0.56   1.76   0.990
  Albumin, per 5 g/l                                0.73         0.58                                             0.92   **0.006**     0.84   0.66   1.08   0.177
  CMV viraemia                                      2.09         1.24                                             3.53   0.004         1.67   0.95   2.93   0.077
  Likelihood ratio test=37.2 on 7 d.f., p\<0.0001                                                                                                           

Bold values are statistically significant at \<0.05.

![Actual and model-fitted monthly TB diagnoses at ART clinic before and after CHW TB-ICF.](JIAS-19-21264-g014){#F0010_72}

![Time to mortality, from randomization date in patients with less than 100 CD4 count and more than 100 CD4 count -- Kaplan-Meier analyses.](JIAS-19-21264-g015){#F0043_074}

###### 

ARV Regimen at Enrollment

  ARV regimen at enrollment   PI+NRTI    Integrase+NRTI   NNRTI+NRTI   Combination (at least 2 of the following classes: PI, NNRTI or integrase)
  --------------------------- ---------- ---------------- ------------ ---------------------------------------------------------------------------
  Number n (%)                50 (47%)   36 (34%)         13 (12%)     7 (7%)

PI: protease inhibitor, NRTI: nucleoside reverse transcriptase inhibitor, NNRTI: non-nucleoside reverse transcriptase inhibitor.

###### 

Effect of Coadministration on HIV ARVs and SOF/VEL

  ARV with SOF/VEL   Effect on SOF/VEL AUC                 Effect on ARV AUC
  ------------------ ------------------------------------- -------------------------------------
  EFV/FTC/TDF        SOF: ↔ GS-331007: ↔ VEL: ↓53%         EFV: ↔ FTC: ↔ TFV: ↑81%
  FTC/RPV/TDF        SOF: ↔ GS-331007: ↔ VEL: ↔            FTC: ↔ RPV: ↔ TFV: ↑40%
  DTG                SOF: ↔ GS-331007: ↔ VEL: ↔            DTG: ↔
  RAL+FTC/TDF        SOF: ↔ GS-331007: ↔ VEL: ↔            RAL: ↔ FTC: ↔ TFV: ↑40%
  DRV/r+FTC/TDF      SOF: ↓28% GS-331007: ↔ VEL: ↔         DRV: ↔ RTV: ↔ FTC: ↔ TFV: ↑40%
  ATV/r+FTC/TDF      SOF: ↔ GS-331007: ↔ VEL: ↑142%        ATV: ↔ RTV: ↔ FTC: ↔ TFV: ↔
  LPV/r+FTC/TDF      SOF: ↓29% GS-331007: ↔ VEL: ↔         LPV: ↔ RTV: ↔ FTC: ↔ TFV: ↔
  EVG/COBI/FTC/TDF   SOF: ↔ GS-331007: ↔ VEL: ↔            EVG: ↔ COBI: ↔ FTC: ↔ TFV: ↔
  EVG/COBI/FTC/TAF   SOF: ↑37% GS-331007: ↑48% VEL: ↑50%   EVG: ↔ COBI: ↔ FTC: ↔ TAF: ↔ TFV: ↔

###### 

Baseline demographics and disease characteristics

  -------------------------------------------------------------------------------------------------------------------------------------------------
                                                                              GT1\                                                GT2\
                                                                              N = 199                                             N = 28
  --------------------------------------------------------------------------- --------------------------------------------------- -----------------
  Male, n (%)                                                                 156 (78)                                            26 (93)

  White race, n (%)                                                           172 (86)                                            25 (89)

  Age, median (range), years                                                  50 (26--69)                                         47 (30--63)

  BMI, median (range), kg/m^2^                                                25 (17--41)[\*](#TF0001_078){ref-type="table-fn"}   24 (15--38)

  HCV genotype 1a, n (%)                                                      147 (74)                                            --

  Cirrhosis, n (%)                                                            22 (11)                                             0

  Treatment-experienced, n (%)                                                64 (33)[†](#TF0002_078){ref-type="table-fn"}        11 (39)

  HCV RNA. median (range), log~10~IU/mL                                       6.5 (1.8--7.6)                                      6.0 (47--7.0)

  CD4+ cell count, median (range), /μL[‡](#TF0003_078){ref-type="table-fn"}   612 (133--2351)                                     731 (262--1533)
  -------------------------------------------------------------------------------------------------------------------------------------------------

BMI, Body Mass Index

N = 198

N = 193

N = 197GT1, N = 27 GT4

###### 

Safety and post-baseline laboratory abnormalities

  ---------------------------------------------------------------------------
  Event, n (%)                                       GT1\         GT2\
                                                     N = 199      N = 28
  -------------------------------------------------- ------------ -----------
  Any AE                                             167 (84)     24 (86)

  Serious AEs                                        9 (5)        1 (4)

  RBV dose modifications due to hemoglobin decline   25 (13)      3 (11)

  ALT Grade ≥3 (\>5×ULN)                             1 (1)        0

  Total Bilirubin Grade \>3 (\>3 \* ULN)             26 (13)      2 (7)

  Patients on ATV-containing ART, n/N (%)            23/26 (88)   2/2 (100)

  Hemoglobin Grade 2 (\< 10 g/dL)                    15 (8)       0

  Hemoglobin Grade 3 (\<8 g/dL)                      0            0
  ---------------------------------------------------------------------------

AE, adverse event, RBV, ribavirin; ALT, alanine aminotransferase; ULN, upper limit of normal; ATV, atazanavir, ART, antiretroviral therapy

###### 

Incidence of HIV infection according to IPERGAY phase

  IPERGAY phase                                       Person-years of follow-up   Incidence of HIV infection per 100 person-years (95% CI)
  --------------------------------------------------- --------------------------- ----------------------------------------------------------
  IPERGAY double-blinded (placebo arm)                212                         6.60 (3.61--11.07)
  IPERGAY double-blinded (TDF-FTC arm)                219                         0.91 (0.11--3.30)
  IPERGAY open-label extension (open-label TDF-FTC)   334                         0.30 (0.00--1.67)

![Self-reported PrEP adherence.](JIAS-19-21264-g016){#F0012_82}

###### 

Correlates of self-reported adherence

                                                                                       ≥90% Self-reported adherence                                               \<50% Self-reported adherence                                                                                                                                         
  ------------------------------------------------------------------------------------ -------------------------------------------------------------------------- ------------------------------------- --------------- ------------------------------------------------------------------------- ------------------------------------- ---------------
  Age ≥25                                                                              2.08 (1.25, 3.45)[\*](#TF0001_82){ref-type="table-fn"}                     1.46 (0.84, 2.54)                     0.1782          0.48 (0.26, 0.86)                                                         1.49 (0.76, 2.95)                     0.2482
  Two-year degree or higher vs. HS or less Some college or vocational vs. HS or less   2.48 (1.28, 4.80)[\*](#TF0001_82){ref-type="table-fn"} 1.11 (0.59, 2.08)   1.59 (0.77, 3.28) 1.02 (0.52, 1.99)   0.2090 0.9513   0.34 (0.15, 0.74) 1.10 (0.55, 2.20)                                       0.46 (0.18, 1.18) 1.06 (0.46, 2.45)   0.1057 0.8922
  Employed FT vs. unemployed PT or self-employed vs. unemployed                        2.66 (1.39, 5.11)[\*](#TF0001_82){ref-type="table-fn"}1.04 (0.56, 1.95)    1.77 (0.85, 3.70) 1.01 (0.52, 1.99)   0.1275 0.9663   0.34 (0.16, 0.76)[\*](#TF0001_82){ref-type="table-fn"}0.90 (0.45, 1.81)   0.76 (0.28, 2.04)1.09 (0.47, 2.52)    0.5801 0.8372
  Poly drug use                                                                        0.46 (0.22, 0.94)[\*](#TF0001_82){ref-type="table-fn"}                     0.49 (0.24, 0.99)                     0.0460          3.22 (1.36, 7.60)[\*](#TF0001_82){ref-type="table-fn"}                    3.30 (1.37, 7.96)                     0.0079
  Primary partner                                                                      1.71 (1.09, 2.69)[\*](#TF0001_82){ref-type="table-fn"}                     1.75 (1.10, 2.79)                     0.0179          0.44 (0.24, 0.82)[\*](#TF0001_82){ref-type="table-fn"}                    0.42 (0.22, 0.82)                     0.0104

AOR, adjusted odds ratio.

The factors included in the adjusted models are the factors that are \<0.05 significance level in the unadjusted model. Analysis was done using generalized estimating equation with exchangeable covariance structure. The behavioural questions were asked for the past 3 months at each visit.

![Cascade coverage and population-level viral suppression among baseline HIV+ adult stable residents of SEARCH Study intervention communities.](JIAS-19-21264-g017){#F0044_084}

![Uptake of PrEP by transgender clients at The Callen-Lorde Community Health Center.](JIAS-19-21264-g018){#F0012_85}

###### 

Countries, periods of observation, duration of follow-up and cumulative mortality between 10 and 15 years of age by region

  Region                      Countries included                                                                                                                                                                                                                                                          N (%)           Observation period   Duration of follow-up during adolescence -- median (IQR) years   Cumulative mortality % (95% CI)
  --------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- -------------------- ---------------------------------------------------------------- ---------------------------------
  South & Southeast Asia      Cambodia, India, Indonesia, Malaysia, Myanmar, Thailand, Vietnam                                                                                                                                                                                                            2902 (7.7)      1994--2014           2.53 (1.17; 4.37)                                                2.98 (2.08; 4.25)
  Europe & Central Asia       Belgium, France, Ireland, Italy, The Netherlands, Poland, Portugal, Romania, Russian Federation, Spain, Sweden, Switzerland, Ukraine, United Kingdom                                                                                                                        3058 (8.1)      1982--2015           6.36 (3.51; 8.01)                                                0.78 (0.50; 1.21)
  South America & Caribbean   Argentina, Brazil, Haiti, Honduras                                                                                                                                                                                                                                          903 (2.4)       1990--2015           4.92 (2.68; 7.37)                                                4.72 (3.33; 6.65)
  North America               United States of America                                                                                                                                                                                                                                                    1048 (2.8)      1991--2014           3.73 (2.01; 5.43)                                                1.09 (0.52; 2.24)
  Sub-Saharan Africa          Benin, Botswana, Burkina Faso, Burundi, Cameroon, Central African Republic, Democratic Republic of Congo, Côte d\'Ivoire, Ethiopia, Ghana, Guinea, Kenya, Lesotho, Malawi, Mozambique, Rwanda, Senegal, South Africa, Swaziland, Tanzania, Togo, Uganda, Zambia, Zimbabwe   29,703 (79.0)   1996--2015           2.04 (0.87; 3.77)                                                3.59 (3.26; 3.96)

###### 

Age, laboratory and anthropometric characteristics of perinatally HIV-infected adolescents (N=37,614) and ranges of medians across regions

                          First visit                        ART start        Age 10 years (±6 months)           Last visit                                                                                              
  ----------------------- ---------------------------------- ---------------- ---------------------------------- ---------------- ---------------------------------- ---------------- ---------------------------------- ----------------
  N                       37,614                                              34,132                                              37,614                                              36,872                             
  Age in years            6.7 (4.4; 8.4)                     0.7; 7.1         7.4 (5.1; 9.1)                     1.0; 7.8         Not applicable                     Not applicable   12.4 (11.0; 14.4)                  12.0; 16.4
  CD4 count in cells/µl   430 (205; 761) N=19,388            255.5; 1282      330 (171; 598) N=19,368            221; 1134        686 (446; 972) N=26,282            639; 797         688 (465; 948) N=31,230            578; 744
  CD4%                    16 (9; 25) N=13,422                10; 30           14 (8; 20) N=14,564                10; 28           28 (20; 34) N=18,029               26; 33           29 (21; 35) N=23,249               27; 32
  Log10 HIV viral load    5.00 (4.35; 5.58) N=4137           4.96; 5.28       4.94 (4.16; 5.51) N=6167           4.83; 5.10       2.42 (1.69; 3.35) N=10,155         1.69; 2.60       2.30 (1.60; 3.18) N=14,006         1.59; 2.60
  WAZ (≤age 10 years)     --1.79 (--2.81; --0.90) N=21,037   --2.71; --0.51   --1.70 (--2.70; --0.83) N=22,908   --2.89; --0.41   --1.42 (--2.18; --0.59) N=30,705   --1.93; 0.09     Not applicable                     Not applicable
  HAZ (all ages)          --1.92 (--2.91; --0.97) N=20,013   --2.37; --0.77   --1.98 (--2.94; --1.05) N=19,801   --2.44; --0.78   --1.54 (--2.36; --0.72) N=26,645   --1.91; --0.32   --1.60 (--2.46; --0.73) N=32,386   --1.78; --0.34
  BMIZ (≥age 5 years)     --0.60 (--1.54; 0.22) N=19,892     --1.44; 0.16     --0.56 (--1.46; 0.25) N=19,697     --1.46; 0.20     --0.54 (--1.26; 0.13) N=26,530     --1.00; 0.38     --0.68 (--1.46; 0.09) N=32,295     --1.02; 0.50
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###### 

Association between cash transfer programme and mental health outcomes in young South African women, HPTN 068

  Outcomes Range, Cronbach\'s alpha                                 CCT n=1214   Control n=1114   RR                                            95% CI         p
  ----------------------------------------------------------------- ------------ ---------------- --------------------------------------------- -------------- ------
  CDI Index (≥7)[a](#TF0001_091){ref-type="table-fn"}, alpha=0.70   25.8%        25.9%            0.99                                          0.85--1.16     0.93
  CES-D (≥16)[a](#TF0001_091){ref-type="table-fn"}, alpha=0.84      28.4%        29.9%            0.96                                          0.86--1.06     0.39
  CMAS Anxiety (0--14), alpha=0.89                                  2.51         2.72             --0.21[b](#TF0002_091){ref-type="table-fn"}   --0.53--0.11   0.19
  Abler Hope (0--39), alpha=0.97                                    31.9         32.0             --0.14[b](#TF0002_091){ref-type="table-fn"}   --0.75--0.48   0.66

≥7 for CDI and ≥16 for CES-D indicates depressive symptoms.

Risk difference.

![Joint alcohol use and VACS index trajectories among study participants.](JIAS-19-21264-g019){#F0013_94}

![Kaplan Meier plot of time to first heavy drinking day by age & and study arm.](JIAS-19-21264-g020){#F0014_095}

###### 

Multivariable models of predictors of unprotected sex among HIV discordant couples

                                                                                 M+F- couples (N=1393)   M-F+ couples (N=1656)                                          
  ------------------------------------------------------------------------------ ----------------------- ----------------------- ------ ---------- ------ ------ ------ ----------
  OCPs                                                                           1.34                    1.19                    1.50   \<0.0001                        
  Injectables                                                                    1.41                    1.23                    1.61   \<0.0001                        
  **Pregnancy status (vs. not pregnant)[a](#TF0001_099){ref-type="table-fn"}**                                                                                          
  Pregnant (not incident)                                                        1.88                    1.74                    2.03   \<0.0001   1.60   1.50   1.71   \<0.0001
  Post-partum (≤6 months)                                                        0.90                    0.76                    1.08   0.260      0.86   0.73   1.02   0.081
  **Woman alcohol use in the past yr (yes vs. no)**                              1.15                    1.01                    1.30   0.041                           
  **Circumcised male partner (yes vs. no)**                                      1.23                    1.04                    1.47   0.019                           

OCP: oral contraceptive pill; IUD: copper intrauterine device; HR: adjusted hazard ratio; CI: confidence interval; yr: year

time-varying variables; p-values are two-tailed

controlling for age, self-reported protected sex with the study partner, self-reported outside sex, and follow-up time since enrolment

controlling for age, self-reported protected sex with the study partner, and follow-up time since enrolment

###### 

Research utilization indicators

  Year of estimation (if mentioned)   Population   Location                        Stakeholders developed an Interpretation and Use Plan for PSE   PSE used to identify a problem   PSE used to develop a plan of action/ recommendation to address that problem   PSE used to change a Global Fund policy as documented in concept notes   PSE used to change a PEPFAR policy as documented in country operational plans   PSE used to change a national MOH policy as documented in NSPs   Study results published in a peer-reviewed academic journal   Results/data translated into non-academic resources (briefs/ pamphlets/ advocacy tools)
  ----------------------------------- ------------ ------------------------------- --------------------------------------------------------------- -------------------------------- ------------------------------------------------------------------------------ ------------------------------------------------------------------------ ------------------------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------- -----------------------------------------------------------------------------------------
  N/A                                 PWID         East Africa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  N/A                                 PWID         South Africa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  N/A                                 PWID         Nigeria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  2009                                MSM-SW       Lagos, Nigeria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  2009                                MSM-SW       Kano, Nigeria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  2009                                MSM-SW       Port Harcourt, Nigeria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  2008, 2009                          FSW          Mauritius                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  2009, 2010                          PWID         Mauritius                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  2010                                MSM          Morocco                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  2010                                PWID         Morocco                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  2010                                FSW          Morocco                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  2010                                PWID         Nairobi, Kenya                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  2009--2010                          FSW          Nairobi, Kenya                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  2010                                MSM          Nairobi, Kenya                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  2012                                PWID         Kenya                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  2012                                FSW          Kenya                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  2012                                MSM          Kenya                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  2012                                FSW          Lagos, Nigeria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  2012                                FSW          Anambra, Nigeria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  2012                                FSW          Nigeria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  2011                                MSM          Luanda, Angola                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  2011--2012                          FSW          Nyanza, Kenya                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  2011--2012                          FSW          Coastal Kenya                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  2011--2012                          FSW          Eastern Kenya                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  2011--2012                          FSW          Central Kenya                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  2011--2012                          FSW          Nairobi, Kenya                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  2011--2012                          FSW          Kenya                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  N/A                                 FSW          Niger                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  2013                                MSM          Yaoundé, Cameroon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  2013                                MSM          Douala, Cameroon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  2013                                MSM          Bamenda, Cameroon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  2013                                MSM          Bertoua, Cameroon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  2013                                MSM          Bafoussam, Cameroon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  2013                                MSM          Ngaoundere, Cameroon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  2013                                MSM          Kribi, Cameroon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  2013                                FSW          Douala, Cameroon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  2013                                FSW          Bamenda, Cameroon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  2013                                FSW          Bertoua, Cameroon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  2013                                FSW          Bafoussam, Cameroon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  2013                                FSW          Ngaoundere, Cameroon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  2013                                FSW          Kribi, Cameroon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  2013                                FSW          Yaounde', Cameroon                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                      MSM          Luanda Province, Angola                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  2010--2013                          PWID         Nador, Morocco                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  2010--2013                          PWID         Tanger, Morocco                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  2010--2013                          FSW          Rabat, Morocco                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  2010--2013                          FSW          Tanger, Morocco                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  2010--2013                          FSW          Fez, Morocco                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  2010--2013                          FSW          Agadir, Morocco                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  2010--2013                          MSM          Marrakesh, Morocco                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  2010--2013                          MSM          Agadir, Morocco                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  2011                                PWID         Dakar, Senegal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  2010                                FSW          Rwanda                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  2010                                FSW          Kigali, Rwanda                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  2011                                FSW          Greater Accra, Ghana                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  2011                                FSW          Ghana                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                      FSW          North Eastern Province, Kenya                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                      FSW          Nairobi province, Kenya                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                      FSW          Urban Kenya                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                      MSM          Kenya                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                      PWID         Kenya                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  2010--2011                          PWID         Coastal Kenya                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                      PWID         Mainland Tanzania                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                      PWID         Kenya                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                      PWID         Zanzibar                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                      PWID         Africa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                      PWID         Eastern Africa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  2013                                FSW          Mekelle, Ethiopia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                      FSW          Durban, South Africa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                      FSW          Mettema Yohannis, Ethiopia                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

![Abstract WEAE0106LB--% of children and adolescents admitted to inpatient wards who received HIV PITC and received results and % of rapid test kit (RTK) stock outs](JIAS-19-21264-g021){#F0045_120}

![Proportion of people living with HIV with diagnosed infection versus those on antiretroviral treatment (ART).](JIAS-19-21264-g022){#F0001_121}

###### 

Outcomes for Participants in the Standard and Same-day ART Groups

                                                                                                Standard group (n=360)   Same-day group (n=360)   p
  --------------------------------- ----------------------------------------------------------- ------------------------ ------------------------ -------------
  **Baseline characteristics**      Female sex -- no. (%)                                       183 (51%)                169 (47%)                0.296
                                    Age -- mean (SD)                                            38 (10)                  38 (10)                  0.296
                                    CD4 count -- mean (SD)                                      244 (129)                241 (124)                0.781
  **Pre-ART outcomes**              Completed CD4 count -- no. (%)                              360 (100%)               360 (100%)               --
                                    Initiated ART within 90 days after HIV testing -- no. (%)   329 (91%)                360 (100%)               **\<0.001**
  **Outcomes 12-months post-ART**   Retained in care -- no. (%)                                 212 (73%)                230 (80%)                **0.046**
    **(among participants with**    Late returners -- no. (%)                                   5 (2%)                   3 (1%)                   0.486
    **12 months of potential**      Lost to follow-up -- no. (%)                                56 (19%)                 46 (16%)                 0.302
    **follow-up time)**             Died -- no. (%)                                             17 (6%)                  8 (3%)                   0.062

The numbers in bold are statistically significant.

![Distribution of first CD4 counts and probability of starting ART at different CD4 counts.](JIAS-19-21264-g023){#F0002_124}

###### 

First-year HIV-Testing and Linkage: case-management outcomes of the Bukoba Tanzania Combination Prevention Evaluation

           HTC outcomes   Linkage case management outcomes                                                              
  -------- -------------- ---------------------------------- ---------- -------- ------ ----------- -------- ---------- ----------
           n              (%)                                n (%)      (%)      n      n (%)       (%)      n (%)      n (%)
  All      56,907         \(64\)                             2292 (4)   \(86\)   1519   1369 (90)   \(83\)   594 (47)   689 (50)
  Female   34,207         \(71\)                             1427 (4)   \(85\)   932    830 (89)    \(81\)   303 (40)   408 (49)
  Male     22,700         \(53\)                             865 (4)    \(88\)   587    539 (92)    \(86\)   291 (57)   281 (52)

###### 

Outcomes of VL cascade analysis

  Site                                                     Buhera, Zimbabwe   Gutu, Zimbabwe   Thyolo, Malawi   Nsanje, Malawi   Roma, Lesotho   Moz Changara (3000 copies/ml is threshold for action throughout algorithm)
  -------------------------------------------------------- ------------------ ---------------- ---------------- ---------------- --------------- ----------------------------------------------------------------------------
  Year routine VL testing started                          2012               2013             2012             2013             2014            2013
  Number of patients in the analysis                       4760               2978             7576             2785             3069            3095
  Coverage of routine VL testing (VL1)                     91%                74%              56%              32%              70%             62%
  VL \> 1000 copies/ml                                     14%                15%              9%               20%              10%             40%
  EAC documented for patients with VL \>1000 copies/ml     57%                76%              62%              56%              70%             70%
  Repeat VL test performed (VL2)                           68%                67%              55%              40%              42%             23%
  Resuppressed to \<1000 copies/ml                         43%                39%              46%              32%              8%              22%
  VL threshold for switch to second-line ART (copies/ml)   1000               1000             5000             5000             1000            3000
  Eligible patients switched to second-line ART            37%                35%              15%              38%              37%             10%

###### 

TVL in two districts in Masvingo Province, Zimbabwe, during 2013--2015

                                                                   2013        2014        2015
  ---------------------------------------------------------------- ----------- ----------- -----------
  Number of patients on ART by year end                            16,506      17,892      21,788
  Patients on ART with 1st VL (N/%)                                150/0.9%    315/1.8%    368/1.7%
  VL test results available (N/%)                                  149/99.3%   313/99.4%   360/97.8%
  VL undetectable (\<20 copies/ml) (N/%)                           44/29.5%    88/28.1%    119/33.1%
  VL detectable at \>3000 copies/ml (N/%)                          76/51.0%    172/55.0%   167/46.4%
  Patients with detectable VL who had a repeat VL done (N/%)       38/50.0%    71/41.3%    52/31.1%
  Patients with confirmed virological failure on repeat VL (N/%)   37/97.4%    55/77.5%    43/82.7%

![Comparison of Xpert HIV-1 RNA Assay using difference plot and passing-bablok regression](JIAS-19-21264-g024){#F0003_131}

![Suppression of HIV-1 replication in PBMCs and CD4+ T-cells of HIV-1 infected patients. PBMCs or CD4+ T-cells from HIV-1 infected volunteers were treated with LV-Cas9 or LV-Cas9 plus LV-gRNAs A/B. **A**. Viral DNA determined by qPCR and normalized to β-globin DNA show decrease in viral copy number with LV-gRNAs. **B**. LV-Cas9 or LV-Cas9 plus LV-gRNA A/B infected CD4+ T-cells show reduction in HIV-1 DNA copy number with LV-gRNAs. **C**. Quantitation of p24 Gag ELISA from infected cells as measure of viral replication.](JIAS-19-21264-g025){#F0004_134}

###### 

Study endpoint table

  Endpoint (time to first event)                                            Continue ART no. no./100 pyr   Discontinue ART no./100 pyr   Hazard Ratio   p-value                        
  ------------------------------------------------------------------------- ------------------------------ ----------------------------- -------------- --------- -------------------- --------
  Primary End point                                                         6                              0.31                          7              0.36      0.87 (0.29, 2.59)    0.80
   AIDS Defining (WHO 4)                                                    2                              0.10                          3              0.15      0.67 (0.11, 4.02)    0.66
   Serious Non-AIDS (Renal)                                                 2                              0.10                          1              0.05      2.00 (0.18, 22.01)   0.56
   Death                                                                    2                              0.10                          4              0.20      0.52 (0.09, 2.81)    0.44
  Secondary End points                                                                                                                                                                 
  Composite Endpoint of HIV/AIDS related events and WHO stage 2--3 events   57                             3.09                          100            5.55      0.56 (0.40, 0.77)    ≤0.001
  WHO 2--3 events                                                           38                             2.02                          80             4.36      0.47 (0.32, 0.68)    ≤0.001
  Grade 2 Toxicity and above                                                260                            18.4                          232            15.4      1.17 (0.98, 1.40)    0.08
  Grade 3 and 4 Toxicity                                                    188                            12.0                          160            9.8       1.21 (0.98, 1.50)    0.07

###### 

Safety overview

  Number of individuals, n (%)                             TDF/FTC/RPV (n=213)                                        TDF/FTC/EFV (n=211)   All Subjects (n=424)
  -------------------------------------------------------- ---------------------------------------------------------- --------------------- ----------------------
  SAEs                                                     16 (7.5%)                                                  11 (5.2%)             27 (6.4%)
  At least one DAIDS grade 3 or 4 AE                       40 (18.8%)                                                 56 (26.5%)            96 (22.6%)
  Fatal AEs                                                1 (myocardial infarction; unrelated to study medication)   0                     1
  Treatment limiting AEs                                   8 (3.8%)                                                   1 (0.5%)              9 (2.1%)
  At least one diabetes/hyperglycaemia event of interest   10 (4.7%)                                                  4 (1.9%)              14 (3.3%)
  At least one neuropsychiatric event of interest          60 (28.2%)                                                 63 (29.9%)            123 (29.0%)

###### 

Baseline Characteristics of patients at time of switch to second line regimen

  Characteristic                                      ATV/r n=285         LTV/r n=215         p
  --------------------------------------------------- ------------------- ------------------- --------
  Age in years, Mean (SD)                             37 (9.0)            37 (9.2)            0.4979
  Sex, n (%)                                                                                  
   Female                                             187 (65.6)          135 (62.8)          0.514
   Male                                               98 (34.4)           80 (37.2)           
  BMI, Median (IQR)                                   22.3 (19.7--54.4)   21.7 (19.3--24.5)   0.1554
  Time (months) on first line therapy, Median (IQR)   39 (22--65)         40 (14--64)         0.0150
  CD4 count cell/µl, Median (IQR)                     109 (53--202)       114 (60--206)       0.5022
  Viral load copies/mm^3^, Median (IQR)               4.8 (4.3--5.2)      4.9 (4.3--5.4)      0.2501

![Abstract THAB0106LB--HIV-infected mothers accepting Early ART after single counselling session](JIAS-19-21264-g026){#F0046_150}

![Incidence of serious AIDS or serious non-AIDS events and NNT by subgroups.](JIAS-19-21264-g027){#F0005_151}

###### 

Suicidal and self-Injurious behaviour

                                                                        No. pts with events (rate per 100 PY)                                                                            
  --------------------------------------------------------------------- ------------------------------------------------ ------ ----------- ----------- ------------------ ------ ------ ------
  By intent-to-treat (ITT) (mean follow-up 3.0 yrs)                     Any regimen (all pts)                            4685   27 (0.39)   24 (0.34)   1.07 (0.6, 1.9)    0.80   NA     NA
  ITT, subgroup analysis (mean follow-up 3.0 yrs)                       EFV based                                        3516   18 (0.34)   11 (0.21)   1.42 (0.7, 3.0)    0.37   1.92   0.23
                                                                        No EFV                                           1169   9 (0.53)    13 (0.72)   0.74 (0.3, 1.8)    0.50          
  ITT, 1st year only, subgroup analysis (mean                           EFV-based                                        3515   9 (0.52)    2 (0.11)    3.75 (0.8. 17.5)   0.09   3.68   0.15
   follow-up 1.0 yrs)                                                   No EFV                                           1169   7 (1.25)    7 (1.19)    1.02 (0.4. 2.9)    0.96          
  Immediate: follow-up from EFV/non-EFV ART start (mean 3.0yrs);        EFV-based[c](#TF0003_152){ref-type="table-fn"}   3516   17 (0.35)   3 (0.08)    4.16 (1.2, 14.4)   0.02   4.00   0.05
  Deferred: Follow-up censored at ART start (mean follow-up 2.1 yrs).   No EFV[d](#TF0004_152){ref-type="table-fn"}      1137   9 (0.59)    8 (0.69)    1.04 (0.4, 2.7)    0.93          

Estimated in CDX proportional hazards models, stratified by psychiatric diagnosis

Interaction between indicators for treatment group and pre-specified regimen

Of these events, 6 and 0, in the immediate us deferred arms respectively, occurred among 108 participants with prior psychiatric diagnoses

Of these events, 5 and 2, in the immediate vs deferred arms respectively, occurred among 162 participants with prior psychiatric diagnoses. Of the 1169 participants without EFV in the pre-specified regimen, 32 were excluded (in the immediate group, 7 never started ART, and for 25, the first ART regimen contained EFV). Follow-up in the immediate group was censored at EFV start.

###### 

Key results from ARIA study in treatment-naïve women

                                                   DTG/ABC/3TC, N = 248   ATV + RTV + TDF/FTC, N = 247
  ------------------------------------------------ ---------------------- ------------------------------
  Race: White (%), African heritage (%)            46, 41                 43, 44
  Median BL CD4+ (cells/mm^3^)                     340                    350
  Median BL HIV-1 RNA (log~10~ c/mL)               4.41                   4.43
  Week 48 HIV-1 RNA \<50 c/mL (Snapshot, %)        82                     71
  Median change in CD4+ at Week 48 (cells/mm^3^)   234                    200
  Virologic failure (Snapshot, %)                  6                      14
  Discontinuations due to AEs (%)                  4                      7
  Pregnancies (%)                                  2                      3
  Drug-related AEs (%)                             33                     49

###### 

Abstract THAB0206LB--Week 48 Outcomes

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Week 48 Snapshot Study Outcomes (ITT-ME)                                                       CAB LA+RPV LA Q8W\                              CAB LA+RPV LA Q4W\                                                                 Oral CAB 30 mg+ABC/3TC (n=56)
                                                                                                 (n=115)                                         (n=115)                                                                            
  ---------------------------------------------------------------------------------------------- ----------------------------------------------- ---------------------------------------------------------------------------------- ---------------------------------------------
  %HIV-1RNA \<50 c/mL at W48:\                                                                   92%[\*\*](#TF0002_156){ref-type="table-fn"}\    91%[\*\*](#TF0002_156){ref-type="table-fn"}\                                       89%
  Dlff in Proportions (95% C1)[\*](#TF0001_156){ref-type="table-fn"}                             (2.9: −6.6, 12.4)                               (2.0: −7.6, 11.6)                                                                  

  Snapshot Virologic Non-response                                                                8 (7%)                                          1 (\<1%)                                                                           1 (2%)

  Data in window not \<50 c/mL                                                                   6 (5%)                                          1 (\<1%)                                                                           0

  Discontinued due to lack of efficacy (PDVF)                                                    1 (\<1%)                                        0                                                                                  1 (2%)

  Discontinued due to Other[\*](#TF0001_156){ref-type="table-fn"} Reasons while Not Suppressed   1 (\<1%)[†](#TF0004_156){ref-type="table-fn"}   0                                                                                  0

  Snapshot No Virologic Data                                                                     1 (\<1%)                                        9 (8%)                                                                             5 (9%)

  Discontinued due to AE or Death                                                                0                                               6 (5%)[†](#TF0004_156){ref-type="table-fn"}[‡](#TF0005_156){ref-type="table-fn"}   2 (4%)[‡](#TF0005_156){ref-type="table-fn"}

  Discontinued due to Other Reasons while Suppressed                                             1 (\<1%)[†](#TF0004_156){ref-type="table-fn"}   3 (3%)                                                                             3 (5%)

  Other Results                                                                                                                                                                                                                     

  Number of injections\                                                                          2126\                                           358S\                                                                              NA
    Number of ISR events\                                                                        1275\                                           1568\                                                                              
    Grade 1 -- mild (%)\                                                                         1017 (80%)\                                     1321 (84%)\                                                                        
  Grade 2 -- moderate (%)\                                                                       245 (19%)\                                      234 (15%)1414 (90%)                                                                
  ISR Duration ≤7 days                                                                           1135 (89%)                                                                                                                         

  Median CD4+ cells/mm^3^ Baseline\                                                              449\                                            499\                                                                               518\
  Change from Baseline\                                                                          +248 (152, 347)                                 +258 (133, 355)                                                                    +307 (199, 566)
  at W48 (IQR)[\*\*\*](#TF0003_156){ref-type="table-fn"}                                                                                                                                                                            
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Intent to Treat- Maintenance Exposed (ITT-ME)

BL=baseline (last value prior to first Induction Period dose at Week −20)

IQR=Interquartile range

W48 represents 68 weeks on study (20 Week Induction Period followed by a 48 Week two drug Maintenance Period)

Met pre-specified threshold for concluding IM regimen is comparable to oral regimen (Bayesian Posterior Probability \>90% that true IM response rate is no worse than −10% compared to the oral regimen)

Based on observed values at Week 48 (Q8W: n=112; Q4W: n=104; Oral: n=50)

Withdrew consent due to intoierabllity of injections

Acute HCV (n=2), rash (n=l), depressive reaction (n=l), psychotic state (n=l), DILI (n=1), Churg Strauss vasculitis (n=l), epilepsy (death) (n=l)

###### 

Characteristics of Incident STIs by PrEP Acceptance and by visit

                               Week 26 PrEP        Week 26 PrEP   Week 52 PrEP       Week 52 PrEP
  ---------------------------- ------------------- -------------- ------------------ --------------
  Site                                                                               
  GWU CRS                      20.0% (11/55)       18.2% (2/11)   21.8% (12/55)      18.2% (2/11)
  UCLA CRS                     14.9% (7/47)        10.5% (2/19)   25.0% (12/48)      22.2% (4/18)
  UNC AIDS CRS                 16.7% (10/60)       0.0% (0/6)     10.9% (7/64)       0.0% (0/6)
  Age                                                                                
  \<25                         25.4% (18/71)       30.0% (3/10)   22.9% (16/70)      16.7% (2/12)
  \> = 25                      11.0% (10/91)       3.8% (1/26)    15.5% (15/97)      17.4% (4/23)
  Baseline Any STI diagnosis                                                         
  No                           12.7% (17/134)      12.1% (4/33)   15.6% (22/141)     16.8% (6/32)
  Yes                          **39.3% (11/28)**   0.0% (0/3)     **34.6% (9/26)**   0.0% (0/3)
  Any condomless sex                                                                 
  No                           14.7% (10/68)       17.4% (4/23)   17.9% (15/84)      12.0% (3/25)
  Yes                          19.8% (16/81)       0.0% (0/11)    17.6% (13/73)      37.5% (3/8)
  Any condomless                                                                     
  receptive Sex                                                                      
  No                           16.2% (16/99)       14.8% (4/27)   16.1% (19/118)     11.1% (3/27)
  Yes                          20.0% (10/50)       0.0% (0/7)     23.1% (9/39)       50.0% (3/6)
  Any condomless                                                                     
  insertive Sex                                                                      
  NO                           19.5% (17/87)       15.4% (4/26)   15.8% (16/101)     11.1% (3/27)
  Yes                          14.5% (9/62)        0.0% (0/8)     21.4% (12/56)      50.0% (3/6)
  Any alcohol/drug 2 hrs.                                                            
  before or during Sex                                                               
  No                           15.8% (15/95)       8.3% (2/24)    15.7% (16/102)     18.5% (5/27)
  Yes                          20.4% (11/54)       20.0% (2/10)   21.8% (12/55)      16.7% (1/6)
  Self-Report adherence                                                              
  \< = 50 pct                                                                        
  No                           16.2% (18/111)      0.0% (0/0)     14.8% (13/88)      0.0% (0/0)
  Yes                          25.9% (7/27)        0.0% (0/0)     35.7% (5/14)       0.0% (0/0)
  Self-Report adherence                                                              
  \>= 90 pct                                                                         
  No                           20.8% (11/53)       0.0% (0/0)     18.2% (6/83)       0.0% (0/0)
  Yes                          16.5% (14/85)       0.0% (0/0)     17.4% (12/69)      0.0% (0/0)
  Average C4 sessions                                                                
  Mean (SD)                    30 (10.2)           28 (13.4)      28 (13.4)          28 (13.4)
  Min, Max                     15, 45              10, 65         10, 65             10, 65
  25th, 75th %tile             23, 40              19, 33         19, 33             19, 33

###### 

National HIV strategy and guidelines by country

  Country     National adolescent health strategy                                                                  Adolescent focus in national HIV strategy/guidelines                                                                                                                                            Disclosure: partial (PD) full (FD)   Transition to adult care
  ----------- ---------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------ ----------------------------------------------------------------
  Kenya       National Adolescent Package of Care, 2014                                                            Integrated in adult guidelines as a separate chapter Referred to as "special population"                                                                                                        PD from 6 years FD by 13--16 years   By 19 years National transition algorithm and evaluation tools
  Zambia      Adolescent Health Strategic Plan, 2011--2015; Adolescent Health Communication Strategy, 2013--2015   Included in consolidated paediatric and adult guidelines as Separate Population                                                                                                                 PD from 5 years FD by 10 years       From 15 years
  Swaziland   National Adolescent Strategic Plan, 2014--2018                                                       Integrated in both paediatric and adult guidelines Separate section in paediatric guidelines "Special Considerations for Adolescents" to address consent, disclosure and psychosocial support   PD at 4--8 years FD at 8--10 years   By 21 years (19--21 years range)
  Lesotho     National Adolescent Health Policy, 2012; Draft Adolescent Health Strategy, 2015                      Included in consolidated paediatric and adult guidelines as Special Population                                                                                                                  PD from 5 years FD from 10 years     By 20 years (15--18 years range)

![Unprotected sex among HIV-positive adolescents by access to social protection interventions (controlling for socio-demographic co-factors).](JIAS-19-21264-g028){#F0012_171}

![Namibia HIV infections impact from programme scale-up scenarios_03Feb2016.](JIAS-19-21264-g029){#F0006_174}

![Six-year ART financing by funding source and region.](JIAS-19-21264-g030){#F0007_175}

![Total PEPFAR funding per person living with HIV (PLHIV) by epidemic category.](JIAS-19-21264-g031){#F0008_176}

###### 

TB/HIV treatment -- October 2014 to September 2015

  Quarter         Total cases detected   Tested for HIV   \% who tested   HIV +   \% HIV +   CPT   \% on CPT   ARV   \% on ART
  --------------- ---------------------- ---------------- --------------- ------- ---------- ----- ----------- ----- -----------
  Oct--Dec 2014   30                     28               93              19      67.9       19    100         8     42
  Jan--Mar 2015   32                     32               100             16      50.0       16    100         14    88
  Apr--Jun 2015   23                     23               100             15      65.2       15    100         13    87
  Jul--Sep 2015   29                     29               100             13      44.8       13    100         13    100

![Sensitivity analysis of the ICER at current and low drug prices.](JIAS-19-21264-g032){#F0009_186}

![Two-way sensitivity analysis of PrEP efficacy and incidence.](JIAS-19-21264-g033){#F0010_187}

###### 

Base case results of an analysis of PrEP cost-effectiveness in Brazil

  Strategy   Total cohort cost/patient   Total cohort LE/patient   HIV+ cases (% of cohort)   \% reduction in lifetime HIV infection risk   Average years to infection (SD)
  ---------- --------------------------- ------------------------- -------------------------- --------------------------------------------- ---------------------------------
  No PrEP    \$4090                      20.7                      50.07                      --                                            13.7 (13.7)
  PrEP       \$3470                      22.4                      31.57                      37                                            24.2 (15.8)

All costs discounted at 3%/year; PrEP: pre-exposure prophylaxis; LE: life expectancy; HIV+: HIV-positive; SD: standard deviation

![All-cause mortality.](JIAS-19-21264-g034){#F0047_193}

![VL and CD4.](JIAS-19-21264-g035){#F0048_194}

###### 

Key efficacy and safety results, ONCEMRK Week 48

  Endpoint                                                                   RAL 1200 mg QD (N = 531)   RAL 400 mg BID (N = 266)   Δ QD-BID (95% CI)
  -------------------------------------------------------------------------- -------------------------- -------------------------- --------------------
  HIV RNA \<40 copies/mL                                                                                                           
   All subjects (NC = F)                                                     88.9%                      88.3%                      0.5 (−4.2, 5.2)
   Baseline vRNA \>100,000 copies/mL (OF)                                    86.7%                      83.8%                      2.9 (−6.5, 14.1)
   Baseline CD4 ≤200 cells/mm^3^ (OF)[†](#TF0001_195){ref-type="table-fn"}   85.1%                      87.9%                      −2.8 (−16.0, 14.0)
   Hepatitis B and/or C co-infection (OF)                                    100%                       85.7%                      14.3 (−11.7, 52.2)
  HIV RNA \<200 copies/mL (NC = F)                                           91.1%                      91.4%                      −0.2 (−4.4, 4.0)
  Mean CD4 Change (95% CI), cells/mm^3^ (OF)                                 232 (215, 249)             234 (213, 255)             −2.1 (−31, 27)
  One or more clinical adverse events                                        82.7%                      86.8%                      −4.2 (−9.2, 1.3)
   Drug-related[‡](#TF0002_195){ref-type="table-fn"} adverse events          24.5%                      25.6%                      −1.1 (−7.6, 5.1)
   Serious adverse events                                                    5.8%                       9.4%                       −3.6 (−8.0, 0.2)
   Serious drug-related adverse events                                       0.2%                       0.8%                       −0.6 (−2.5, 0.4)
   Discontinued[§](#TF0003_195){ref-type="table-fn"} due to adverse event    0.8%                       2.3%                       −1.5 (−4.1, 0.1)

All subjects also received tenofovir/emtricitabine.

Combination of two pre-specified groups (550 and \>50 to £200 cells/mm^3^).

Determined by the investigator to be related to study drug.

Study medication withdrawn.

NC = F: Non-Completer = Failure, as defined by FDA snapshot approach (all missing data treated as failures); OF: Observed Failure approach.

###### 

Mean number of HIV and sexually transmitted infection (STI) tests over 12 months in intention-to-treat population. Mean(SD) unless otherwise specified

                                Overall     Frequent testers   Infrequent testers                                                                              
  ----------------------------- ----------- ------------------ ----------------------- ----------- ----------- ----------------------- ----------- ----------- -----------------------
  **Self/facility-based HIV**   3.9 (0.2)   1.6 (0.1)          **2.39 (2.08--2.76)**   4.0 (0.2)   1.8 (0.1)   **2.23 (1.93--2.59)**   3.2 (0.5)   0.6 (0.2)   **5.54 (3.15--9.74)**
  **Facility-based HIV**        1.4 (0.1)   1.6 (0.1)          0.89 (0.75--1.06)       1.6 (0.1)   1.8 (0.2)   0.88 (0.73--1.05)       0.8 (0.3)   0.6 (0.2)   1.41 (0.73--2.73)
  **Any STI**                   1.6 (0.1)   1.7 (0.2)          0.93 (0.79--1.10)       1.8 (0.1)   1.9 (0.2)   0.92 (0.77--1.09)       0.9 (0.3)   0.7 (0.2)   1.35 (0.73--2.49)
  **Chlamydia/ Gonorrhoea**     1.5 (0.1)   1.6 (0.1)          0.94 (0.80--1.12)       1.6 (0.1)   1.8 (0.2)   0.93 (0.78--1.11)       0.9 (0.3)   0.6 (0.2)   1.33 (0.71--2.50)
  **Syphilis**                  1.4 (0.1)   1.5 (0.1)          0.90 (0.76--1.08)       1.5 (0.1)   1.7 (0.1)   0.89 (0.74--1.07)       0.8 (0.3)   0.6 (0.2)   1.41 (0.72--2.76)

The bold values in the table are statistically significant (p\<0.001).

![Provider and patient interest in a PrEP home testing system and home counselling system.](JIAS-19-21264-g036){#F0011_214}

###### 

Mean wait time and time receiving services by patient types

                                SEARCH Patients CD4=500 (hours:minutes) mean (SD)   SEARCH Patients CD4\<500 (hours:minutes) mean (SD)   Other government clinic patients (hours:minutes) mean (SD)
  ----------------------------- --------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------
  Total visit length            1:08 (1:02)                                         1:13 (1:03)                                          2:35 (1:33)
  **Wait time before visit**    **0:21 (0:36)**                                     **0:28 (0:43)**                                      **1:13 (1:13)**
  **Wait time during visit**    **0:19 (0:30)**                                     **0:23 (0:35)**                                      **0:58 (1:00)**
  **Time receiving services**   **0:27 (0:24)**                                     **0:22 (0:20)**                                      **0:24 (0:29)**
  --Health education            \<0:01 (0:03)                                       0:01 (0:07)                                          0:08 (0:21)
  --HIV care                    0:18 (0:18)                                         0:12 (0:11)                                          0:08 (0:13)
  --Laboratory services         0:03 (0:09)                                         0:01 (0:08)                                          0:01 (0:08)
  --Medication dispensing       0:01 (0:02)                                         0:03 (0:07)                                          0:04 (0:10)
  --Other                       0:03 (0:09)                                         0:03 (0:09)                                          \<0:01 (0:05)

Reference
=========

1\. Tamura K, Peterson D, Peterson N, Stecher G, Nei M and Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011 Oct;28(10):2731--9.

Reference
=========

1\. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000;356:930--933.

![Graph of rate to mutation development after failure and percentage of patients with each number of mutations after failure.](JIAS-19-21264-g037){#F0026_236}

![South African HIV care cascade by sex and age group, April 2014--March 2015.](JIAS-19-21264-g038){#F0027_239}

###### 

Sexual behaviour at baseline, 12 and 24 months in the START Trial: comparison of immediate ART versus deferred ART in MSM and heterosexuals

  *p- values by chi-squared tests*                                    MSM immediate ART (N=1314)   MSM deferred ART (N=1306)   p         Heterosexual immediate ART (N=1012)   Heterosexual deferred ART (N=1053)   p
  ------------------------------------------------------------------- ---------------------------- --------------------------- --------- ------------------------------------- ------------------------------------ ---------
  **Baseline CLS[\*](#TF0001_242){ref-type="table-fn"}**              427/1090 (39.2%)             429/1094 (39.2%)                      239/914 (26.1%)                       253/941 (26.9%)                      
  **12 months CLS**                                                   359/1201 (29.9%)             367/1148 (32.0%)            0.28      177/909 (19.5%)                       195/931 (20.9%)                      0.43
  **24 months CLS**                                                   357/1062 (33.6%)             349/1032 (33.8%)            0.92      153/719 (21.3%)                       110/714 (15.4%)                      0.004
  **Baseline CLS-D[\*](#TF0001_242){ref-type="table-fn"}**            253/1281 (19.8%)             257/1283 (20.0%)                      132/1002 (13.2%)                      122/1039 (11.7%)                     
  **12 months CLS-D**                                                 156/1232 (12.7%)             155/1185 (13.1%)            0.76      101/933 (10.8%)                       80/959 (8.3%)                        0.066
  **24 months CLS-D**                                                 173/1064 (16.3%)             152/1035 (14.7%)            0.32      69/724 (9.5%)                         40/720 (5.6%)                        0.004
  **Baseline CLS-D-HIV-risk[\*](#TF0001_242){ref-type="table-fn"}**   253/1281 (19.8%)             257/1283 (20.0%)                      132/1002 (13.2%)                      122/1039 (11.7%)                     
  **12 months CLS-D-HIV-risk**                                        3/1232 (0.2%)                130/1185 (11.0%)            \<0.001   6/933 (0.6%)                          74/959 (7.7%)                        \<0.001
  **24 months CLS-D-HIV-risk**                                        6/1064 (0.6%)                97/1035 (9.4%)              \<0.001   6/724 (0.8%)                          33/720 (4.6%)                        \<0.001

See "Methods" for definitions of (i) CLS, (ii) CLS-D (iii) CLS-D-HIV-risk.

![Trends of improved linkages to care of newly diagnosed HIV infected persons between Oct 2012 and Sept 2015.](JIAS-19-21264-g039){#F0001_267}

###### 

Mean change in eGFR by randomization arm in INSIGHT START trial

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome        Model 1[\*](#TF0001_273){ref-type="table-fn"}\   Adjusted Model 2[\*\*](#TF0002_273){ref-type="table-fn"}\   Adjusted Model 3[\*\*\*](#TF0003_273){ref-type="table-fn"}\
                 Deferred arm (vs. immediate arm)\                Deferred arm (vs. immediate arm)\                           Deferred arm (vs. immediate arm)\
                 (95% CI), P                                      (95% CI), P                                                 (95% Cl), P
  -------------- ------------------------------------------------ ----------------------------------------------------------- -------------------------------------------------------------
  eGFR-CKD-EPI   −0.56 (−1.11 to −0.003), 0.049                   −1.85 (−2.50 to −1.21), \<0.001                             −1.72 (−2.34 to −1.11), \<0,001

  eGFR-MDRD      −1.26 (−2.14 to −0.38), 0.005                    −3.43 (−4.51 to −2.35), \<0.001                             −3.21 (−4.25 to −2.17), \<0.001
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Model 1: adjusted for baseline eGFR and years since randomization.

Model 2: additionally adjusted for current receipt of TDF and boosted PI.

Model 3: Model 2 + additionally adjusted for age, gender, race, region of enrollment, time since HIV diagnosis, use of injecting drugs, CD4, viral load, proteinuria, body mass index, hepatitis B/C, diabetes, hypertension, dyslipidaemia, cardiovascular disease, smoking status, ACE inhibitors or NSAIDS, all measured at randomization.

![Age distribution in CoRIS since 2004 to 2014.](JIAS-19-21264-g040){#F0001_277}

###### 

Incidence rates (95% CI) per 1000 person-years for each comorbidity by age group

                                                                                   Rate (95% CI) per 1000 person-years, by age group                                              
  -------------------------------------------------------------------------- ----- --------------------------------------------------- ------------------- ---------------------- ---------
  **Cardiovascular**                                                         85    2.49 (2.01--3.08)                                   1.38 (1.01--1.88)   8.75 (6.53--11.72)     \<0.001
  **kidney-associated event**                                                89    2.61 (2.12--3.21)                                   2.07 (1.61--2.67)   5.60 (3.89--8.06)      \<0.001
  **Liver-associated event**                                                 94    2.76 (2.25--3.37)                                   2.63 (2.10--3.29)   3.46 (2.18--5.48)      0.299
  **Bone**                                                                   122   3.58 (3.00--4.28)                                   3.19 (2.60--3.91)   5.81 (4.06--8.31)      0.004
  **Psychiatric**                                                            212   6.30 (5.50--7.20)                                   6.30 (5.44--7.29)   6.28 (4.44--8.88)      0.987
  **Metabolic**                                                              87    2.55 (2.07--3.15)                                   1.69 (1.28--2.24)   7.40 (5.38--10.17)     \<0.001
  **Other non-AIDS infections**                                              11    0.32 (0.18--0.58)                                   0.27 (0.14--0.55)   0.57 (0.18--1.77)      0.281
  **Non-AIDS malignancies (more than one event per person is considered)**   181   5.32 (4.60--6.16)                                   5.16 (4.40--6.06)   13.61 (10.77--17.20)   \<0.001

![Association between vaginal bacterial concentration and odds of HIV acquisition.](JIAS-19-21264-g041){#F0001_285}

![The association between enrollment in the HIV prevention trial in 2011 and school enrollment in 2011, 2012, and 2013, stratified by age, in both the full cohort, and a restricted cohort of those enrolled in school in 2011.](JIAS-19-21264-g042){#F0031_289}

###### 

Crude and Adjusted Differences in Mean Bayley-III Scores

                        Mean (SD) scores   Unadjusted differences   Adjusted differences                  
  --------------------- ------------------ ------------------------ ---------------------- ------ ------- ------
  Cognitive             53.75 (3.37)       53.07 (3.25)             0.68                   0.01   0.60    0.02
  Gross motor           52.66 (2.77)       52.91 (2.67)             −0.25                  0.25   −0.14   0.51
  Fine motor            37.25 (1.80)       37.35 (1.80)             −0.10                  0.46   −0.07   0.63
  Expressive language   25.02 (4.36)       25.85 (3.98)             −0.83                  0.01   −0.49   0.14
  Receptive language    21.07 (3.54)       20.76 (3.21)             0.31                   0.24   0.14    0.61

![Weight-for-age Z scores over time: comparisons.](JIAS-19-21264-g043){#F0032_315}

Reference
=========

1\. Hillemann D., et al. 2011. Rapid Molecular Detection of Extrapulmonary Tuberculosis by the Automated GeneXpert MTB/RIF System. J Clin Microbiol. 49(4): 1202--1205.

![Performance of HIV-1/2/O EIA on reconstituted seroconversion panel members (PRB947 and PRB910, SeraCare) eluted from HemaSpot (HS) or DBS.](JIAS-19-21264-g044){#F0033_321}

![Probability of reported partner pregnancy over time among HIV-positive men on ART in Mbarara, Uganda.](JIAS-19-21264-g045){#F0001_330}

![Cost-per-HIV infection averted by CVCT in countries with a range of HIV.](JIAS-19-21264-g046){#F0035_342}

![Economies of scale in HIV prevention services: Kenyan health facilities, 2011--12.](JIAS-19-21264-g047){#F0036_343}

###### 

Average cost (US\$) per client across HIV prevention service cascade in Kenyan health facilities, 2011--12

                                                     N (facilities)   Mean      Patient-volume weighted mean   Median   Standard deviation   IQR
  ------------ ------------------------------------- ---------------- --------- ------------------------------ -------- -------------------- ---------
  **HTC:**     Cost per client tested                56               7.4       6.5                            4.8      7.1                  5.9
               Cost per client tested and positive   56               145.9     80.2                           54.9     318.0                74.7
  **PMTCT:**   Cost per client tested                57               57.4      47.3                           32.7     84.8                 60.5
               Cost per client tested and positive   49               677.2     753.9                          254.2    1,056.8              571.6
               Cost per client on ART                14               2,472.6   1,752.6                        364.6    5,464.7              1,689.9

![Comparing Annual Pediatric Costs and Patient Volumes: WHO 2013 vs. 2015 Guidelines.](JIAS-19-21264-g048){#F0037_344}

![Decreasing prices of exported sofosbuvir/daclatasvir through 2015. 1 bubble = 1 shipment, bubble area scaled to size of shipment in kg.](JIAS-19-21264-g049){#F0001_347}

###### 

Calculated target prices and current prices for 12-week DAA treatment courses

  Drug               End-2015 API cost/kg   Target price per 12-week treatment   Current global lowest price per 12-week treatment   Current US price per 12-week treatment
  ------------------ ---------------------- ------------------------------------ --------------------------------------------------- ----------------------------------------
  Sofosbuvir (SOF)   \$1,758                \$95                                 \$483                                               \$84,000
  Daclatasvir        \$1,432                \$17                                 \$183                                               \$63,000
  Ledipasvir (LDV)   \$11,432               \$136                                unknown                                             unknown
  SOF + LDV          N/A                    \$231                                \$615                                               \$94,500
  Velpatasvir        \$8,900--11,700        \$119--154                           unknown                                             unknown

  ------------------------------ -------------------------------------------------------------------------
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